MyLungCancerTeam

Yes, there are two FDA-approved targeted therapies specifically for lung cancers with KRAS mutations: Sotorasib (Lumakras) and Adagrasib (Krazati). These medications are typically given to patients who have tried at least one other treatment first. This is actually an exciting development in lung cancer treatment because Show Full Answer

Yes, there are two FDA-approved targeted therapies specifically for lung cancers with KRAS mutations: Sotorasib (Lumakras) and Adagrasib (Krazati). These medications are typically given to patients who have tried at least one other treatment first. This is actually an exciting development in lung cancer treatment because KRAS mutations were previously considered resistant to drug therapy. These medications specifically target the KRAS G12C mutation, which occurs in about 13-25% of non-small cell lung cancer cases. The treatments work by blocking signals that tell cancer cells to grow and divide uncontrollably.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

6 Lung Cancer Mutations and Treatments That Target Them

2021 Highlight: FDA Expanded Lung Cancer Treatment Options With Four New Drugs